Eli Lilly Reveals Full Phase 3 Data for Retatrutide in Obesity Treatment | Retatrutide News

Eli Lilly has released full phase 3 data for Retatrutide, a GLP-1 agonist, in obesity treatment. This positions Retatrutide as a key player in the next-...
Clinical Trials · October 21, 2026